Clinical trials: Age Related Symptoms
Fatigue, Aging
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
This is a pilot study funded by the National Institutes of Health. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on muscle strength and physical function in older…
- Trial name
- NCT01059994
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
HIV, Aging
Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients
This study is designed to evaluate specific factors in mitochondria that may precipitate premature aging and physical weakness in HIV patients. Angiotensin receptors 1 and 2 (AT1R and AT2R) are found in virtually every cell type.
- Conditions
- HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
- Trial name
- RAS-HIV (NCT02606279)
- Testing
- valsartan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Muscle Loss, Fractures
Musculoskeletal Effects of Bicarbonate
With aging, men and women develop a mild and progressive metabolic acidosis. This occurs as a result of declining renal function and ingestion of acid-producing diets.
- Conditions
- Muscle Loss, Fractures, Osteoporosis, Age Related, Fall Injury
- Trial name
- NCT01475214
- Testing
- potassium bicarbonate
- Where
- United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Tufts University
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Choroidal Neovascularization
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib…
- Trial name
- VERITAS (NCT00242580)
- Testing
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Seasonal Allergic Rhinitis
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.
- Trial name
- NCT00653224
- Testing
- levocetirizine dihydrochloride
- Where
- 38 sites in United States
- Volunteers
- 580 people
- Sponsor
- UCB Pharma
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research
Deafness, Blindness
Workshops for Veterans With Vision and Hearing Loss
This is a pilot study of workshops to help Veterans with both vision and hearing loss live a happier, fuller and less stressful life. The results will be used to guide the development of a large scale clinical trial.
- Trial name
- DSLW (NCT01109576)
- Testing
- DSL Workshop
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- US Department of Veterans Affairs
Age-Related Hearing Loss
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.
- Trial name
- CLARITY-1 (NCT02345031)
- Testing
- AUT00063
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Autifony Therapeutics Limited
Sarcopenia, Gait Disorders in Old Age
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-INT (NCT03452488)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium
- Volunteers
- 233 people
- Sponsor
- Biophytis
Neovascular Age-related Macular Degeneration
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen…
- Trial name
- NCT01027468
- Testing
- Bevacizumab
- Volunteers
- 160 people
- Sponsor
- Medical University of Vienna
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Hearing Loss, Depression
Treating Hearing Loss to Improve Mood and Cognition in Older Adults
Age-related hearing loss (ARHL) is the third most common health condition affecting older adults after heart disease and arthritis and is the fifth leading cause of years lived with disability worldwide.
- Trial name
- NCT03321006
- Testing
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Exudative Age-related Macular Degeneration
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination…
- Trial name
- TOFU (NCT04200248)
- Testing
- RBM-007 Injectable Solution, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Ribomic USA Inc
Macular Degeneration, Choroidal Neovascularization
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in…
- Trial name
- NCT00436553
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 43 sites in United States, Canada
- Volunteers
- 321 people
- Sponsor
- Novartis
Low Vision, Age Related Macular Degeneration
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration.
- Trial name
- NCT04984590
- Testing
- IOPCL AMD MAG
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc